CF PharmTech, Inc. (CF PharmTech) reported a new on-market share repurchase on 09 June 2026 under its existing mandate. Key takeaways are as follows:

• Transaction details: 31,000 H-shares were repurchased on the Hong Kong Stock Exchange at prices between HKD 18.52 and HKD 19.14, with a volume-weighted average cost of HKD 18.91 per share. The aggregate consideration amounted to HKD 0.59 million.

• Capital structure impact: The issued share capital (excluding treasury shares) declined from 300.95 million to 300.92 million shares, a reduction of 0.0103%. All repurchased shares are being held as treasury stock, lifting the treasury share balance to 1.30 million. No shares have been cancelled to date. Total issued shares remain at 302.22 million.

• Mandate utilisation: The current repurchase mandate, granted on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases now stand at 1.30 million shares, representing 0.43% of the issued share count on the mandate date.

• Moratorium period: In line with Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 09 July 2026.

The board confirms that the repurchase complied with all applicable regulations and there have been no changes to the explanatory statement previously filed with the Exchange.